openPR Logo
Press release

Urothelial Carcinoma Diagnostics Market 2022 Global Projection By Key Players - GE Healthcare, Roche Holding, Illumina, IDL Biotech- Analysis and Forecast to 2030

05-17-2022 05:57 PM CET | Health & Medicine

Press release from: Persistence Market Research

/ PR Agency: Persistence Market Research
Urothelial Carcinoma Diagnostics Market 2022

Urothelial Carcinoma Diagnostics Market 2022

Urothelial Carcinoma Diagnostics Market 2022

The pharmaceutical industry is making use of AI for discovering new-fangled drugs. January 2020 witnessed the invention of the very first drug molecule using AI, whose patent lay with Japanese and British scientists. The medicine is being used for treating OCD (obsessive-compulsive disorder). Likewise, several promising formulas are being discovered as an outcome of AI-enabled lab experimenting. This would be how the pharmaceutical arm of the healthcare vertical look shortly.

According to the latest report published by PMR, the global urothelial carcinoma diagnostics market was valued at US$ 1 Bn in 2020, and is expected to progress at a CAGR of over 11% during the forecast period (2020-2030).

Get Free Sample Copy Of Urothelial Carcinoma Diagnostics Market Report@ https://www.persistencemarketresearch.com/samples/14128

According to World Health Organization (WHO) estimates, every year, 3.8 Mn new cases of urothelial carcinoma occur around the world, with the recurrence rate being nearly 30-50%. However, early detection by use of modern diagnostics enables quick medical decision-making and consequent treatment for urothelial carcinoma. Accuracy in urothelial carcinoma diagnostics plays a significant role in the reduction of treatment costs.

Moreover, increased demand for treatment of urothelial carcinoma is a key driver for increasing revenue inflow from diagnostic tests and procedures. However, development of effective urothelial carcinoma screening methods will play a significant role in the early detection and subsequent reduction in mortality rates. Furthermore, technological advancements in diagnostic methods such as the adoption of diagnostic imaging procedures, rapid molecular diagnostic kits, and use of biomarker testing in urothelial carcinoma screening programs are some other factors that will aid the growth of the urothelial carcinoma diagnostics market.

Companies covered in Urothelial Carcinoma Diagnostics Market Report

GE Healthcare
Roche Holding
Illumina
IDL Biotech
Agilent Technologies
Olympus Corporation
Philips Healthcare
Abbott Molecular
Bio-Rad Laboratories, Inc
Thermo Fisher Scientific, Inc.( Qiagen N.V.)
Danaher Corporation (Cepheid)

Look Through The "Methodology" Employed@ https://www.persistencemarketresearch.com/methodology/14128

 Key Takeaways from Urothelial Carcinoma Diagnostics Market Study         

The reagent and kits segment, under product type, is expected to contribute more than 70% of revenue share in the urothelial carcinoma diagnostics market.

By test type, molecular diagnostic tests accounted for the highest revenue in 2019. Rapid and sensitive detection is anticipated to drive demand for urothelial carcinoma diagnostics.

Based on end user, the hospitals segment accounts for a major revenue share in the urothelial carcinoma diagnostics market.

Leading players launching rapid diagnostic products with advances technology are expected to dominate the urothelial carcinoma diagnostics market space.

Governments of various countries are organizing cancer screening programs and are spreading awareness, which is creating significant demand for urothelial carcinoma diagnostics.

The COVID-19 outbreak has resulted in manufacturing disruptions and also decreased demand, which is projected to impede market growth in the near term.

Purchase Our Urothelial Carcinoma Diagnostics Market Report Now@ https://www.persistencemarketresearch.com/checkout/14128

"Rise in prevalence of urothelial carcinoma and demand for early detection for preventive treatments will boost the global urothelial carcinoma diagnostics market," says a PMR analyst.

Acquisitions and Partnerships - Key Strategies amongst Market Players

Key players in the urothelial carcinoma diagnostics market are looking forward to strengthening their product portfolios through the launch of new products. For instance, in 2017, Roche received FDA approval for the complementary PD-L1 (SP263) biomarker test in urothelial carcinoma. In August, 2018, Agilent Technologies, Inc announced that the US Food and Drug Administration approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use as a companion diagnostic test for Merck's anti-PD1 immunotherapy Keytruda (pembrolizumab) for urothelial carcinoma.

Various players in the urothelial carcinoma diagnostics market are focusing on growth strategies such as acquisitions and partnerships. For example, in 2020, Thermo Fisher Scientific signed an agreement with Janssen to co-develop companion diagnostics for cancer.

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the urothelial carcinoma diagnostics market in its latest study, presenting historical demand assessment of 2015-2019 and projections for 2020-2020, on the basis of product type (reagents and kits, instruments), test type (urinalysis test, molecular diagnostic test, biomarker test, imaging test, cytoscopy, ureteroscopy), and end user (hospitals, diagnostic laboratories, research and academic institutes, clinical research organizations), across seven key regions.

Related Reports:

Meniscus Repair Systems Market - 

https://www.persistencemarketresearch.com/market-research/meniscus-repair-systems-market.asp

Heel Pressure Injury Relieving Devices Market - https://www.persistencemarketresearch.com/market-research/heel-pressure-injury-relieving-devices-market.asp

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us: 

PersistenceMarketResearch is an esteemed company with a reputation of serving clients across domains of information technology (IT), healthcare, and chemicals. Our analysts undertake painstaking primary and secondary research to provide a seamless report with a 360 degree perspective. Data is compared against rep/uted organizations, trustworthy databases, and international surveys for producing impeccable reports backed with graphical and statistical information.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Urothelial Carcinoma Diagnostics Market 2022 Global Projection By Key Players - GE Healthcare, Roche Holding, Illumina, IDL Biotech- Analysis and Forecast to 2030 here

News-ID: 2627268 • Views:

More Releases from Persistence Market Research

Frozen Foods Market Heats Up with Innovation and Growing Consumer Demand
Frozen Foods Market Heats Up with Innovation and Growing Consumer Demand
Market Overview: The frozen foods market consists of a wide range of products, including frozen fruits and vegetables, meat and seafood, ready-to-eat meals, and desserts. These products are preserved through freezing to maintain freshness and quality for an extended period. Market Size and Growth: The global market for frozen foods is forecasted to be of valuation US$ 281.0 Billion in the year 2022 which is expanding at a value CAGR of 5.1% and
The Global Graphene Market's Striking Growth and Innovative Applications
The Global Graphene Market's Striking Growth and Innovative Applications
Introduction Graphene, a single layer of carbon atoms arranged in a hexagonal lattice, has gained global recognition for its extraordinary properties, such as exceptional electrical and thermal conductivity, mechanical strength, and flexibility. Since its isolation in 2004 by Andre Geim and Konstantin Novoselov, graphene has sparked considerable interest in both scientific and industrial communities. This report explores the current state of the graphene market and its potential growth opportunities. Get Access To
Business Opportunities in Cyber Security Mesh Market : Top Countries Data Analysis, Emerging Trends with Upcoming Developments
Business Opportunities in Cyber Security Mesh Market : Top Countries Data Analys …
Market Overview: The projected global market size for cyber security mesh is expected to reach $8.8 billion by the year 2033, with an estimated valuation of $1.2 billion by 2023. This market is poised to experience a compound annual growth rate (CAGR) of 21.7% from 2023 to 2033. The global Cyber Security Mesh market is poised for significant growth as organizations worldwide grapple with the escalating threat landscape. Cybersecurity has become an
Synthetic Beta-Carotene Market To Boost Incredible Growth: 2033, Share Valuation and Industry Size
Synthetic Beta-Carotene Market To Boost Incredible Growth: 2033, Share Valuation …
Key market trends included a shift towards natural and plant-based ingredients, as consumers sought cleaner labels and healthier options. This drove the demand for naturally sourced beta-carotene, but synthetic beta-carotene still had its place due to its cost-effectiveness and consistency in production. The market was also influenced by regulatory changes and evolving dietary preferences, which affected the application and formulation of synthetic beta-carotene in various products. To obtain the latest market

All 5 Releases


More Releases for Urothelial

Urothelial Cancer Drugs Market Report Up to 2031
Visongain has published a new report on Urothelial Cancer Drugs Market Report 2021-2031: Forecasts by Type (Urothelial Carcinoma, Squamous Cell Carcinoma, and Adenocarcinoma), by Treatment (Chemotherapy, Immunotherapy). PLUS Profiles of Leading Pharma Contract Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios. Global Urothelial Cancer Drugs market was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx
Sacituzumab Govitecan Approval for Advanced or Metastatic Urothelial Cancer
On April 13, 2021, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Sacituzumab Govitecan (from Gilead Sciences) for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor. Sacituzumab govitecan is a first-in-class Trop-2-directed antibody-drug conjugated to a topoisomerase I inhibitor (SN-38). Trop-2 receptor, a protein frequently expressed in multiple types
European Urothelial Carcinoma Market Research and Forecast 2020-2026
European urothelial carcinoma market is estimated to grow significantly at a CAGR of around 9.2%, during the forecast period. The growth of the market is attributed to well-developed healthcare infrastructure, significant healthcare expenditure, and growing prevalence and incidence of urothelial carcinoma across many European economies. Sedentary lifestyle such as smoking, consumption of drugs, and alcohol in European countries are the major factors for the growing incidence of urothelial carcinoma among
Urothelial Carcinoma Treatment Market to Record Study Growth by 2024
Urothelial carcinoma is a malignant neoplasm resulting from transitional epithelium, occurring mainly in the urinary bladder, renal pelves or ureters; frequently papillary. These carcinomas are classified according to the degree of anaplasia. Urothelial cell carcinoma (UCC) is a type of cancer that normally occurs in the urinary system: urinary bladder, kidney and accessory organs. It is the most common type of bladder, ureter, urethra, and urachus cancer. Urothelial cell carcinoma
Urothelial Carcinoma Diagnostics Market Forecast over 2017 – 2025
Urothelial Carcinoma or Transitional Cell Carcinoma encompasses cancer in different parts of urinary tract like kidney, bladder, ureters, and renal pelvis. Bladder tumors account for 90-95% of urothelial carcinoma. Urothelial Carcinoma occur more commonly in men than in women with the ratio of 3:1. Tobacco smoking, Coffee drinking, analgesic abuse, some occupational exposures are the factors that promote urothelial carcinoma. The urothelial carcinoma diagnosis involves the tests that are used
Urothelial Carcinoma Treatment Market : Trends and Key Developments 2016 - 2024
Urothelial carcinoma is a malignant neoplasm resulting from transitional epithelium, occurring mainly in the urinary bladder, renal pelves or ureters; frequently papillary. These carcinomas are classified according to the degree of anaplasia. Urothelial cell carcinoma (UCC) is a type of cancer that normally occurs in the urinary system: urinary bladder, kidney and accessory organs. It is the most common type of bladder, ureter, urethra, and urachus cancer. Urothelial cell carcinoma